{"analyses":[{"ciLowerLimit":"0.46","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.31","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.34","paramType":"Hazard Ratio (HR)","paramValue":"0.78","statisticalComment":"Adjusted on the stratification factor (treatment centers)","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"55","upperLimit":"75","value":"65"},{"groupId":"OG001","lowerLimit":"64","upperLimit":"81","value":"73"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"98"},{"groupId":"OG001","value":"105"}],"units":"Participants"}],"description":"To evaluated the overall survival in both groups in participants presenting fast and slow decrease in serum levels of tumor markers. The median overall survival was defined as the median percentage of participants alive after 1 course of treatment.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive 4 courses of bleomycin, etoposide, and cisplatin (BEP).\n\nbleomycin sulfate: At least one course administered\n\ncisplatin: At least one course administered\n\netoposide: At least one course administered","id":"OG000","title":"Arm I"},{"description":"Patients receive 1 course of bleomycin, etoposide, and cisplatin (BEP). Patients then receive dose-dense sequential combination chemotherapy comprising cisplatin, etoposide, bleomycin, paclitaxel, oxaliplatin, and ifosfamide.\n\nbleomycin sulfate: At least one course administered\n\ncisplatin: At least one course administered\n\netoposide: At least one course administered\n\nifosfamide: Given in a dose-dense sequential fashion\n\noxaliplatin: Given in a dose-dense sequential fashion\n\npaclitaxel: Given in a dose-dense sequential fashion","id":"OG001","title":"Arm II"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"3 years from randomization","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"percentage of participants"}